These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 8644760

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol.
    Antezana G, Zeballos R, Mendoza C, Lyevre P, Valda L, Cardenas F, Noriega I, Ugarte H, Dedet JP.
    Trans R Soc Trop Med Hyg; 1992; 86(1):31-3. PubMed ID: 1566297
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F.
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [Abstract] [Full Text] [Related]

  • 45. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.
    de Vallière S, Mary C, Joneberg JE, Rotman S, Bullani R, Greub G, Gillmore JD, Buffet PA, Tarr PE.
    Am J Trop Med Hyg; 2009 Aug; 81(2):209-12. PubMed ID: 19635871
    [Abstract] [Full Text] [Related]

  • 46. Control of visceral leishmaniasis in Somalia: achievements in a challenging scenario, 2013–2015.
    Wkly Epidemiol Rec; 2017 Sep 22; 92(35):566-72. PubMed ID: 28945058
    [No Abstract] [Full Text] [Related]

  • 47. Retention of antimony in hair during leishmaniasis treatment.
    Dorea JG, Merchan-Hamann E, Ryan DE, Holzbecher J.
    Clin Chim Acta; 1989 Feb 22; 179(3):341-5. PubMed ID: 2714007
    [No Abstract] [Full Text] [Related]

  • 48. The chemotherapy of protozoal infections: whither?
    Steck EA.
    J Protozool; 1981 Feb 22; 28(1):30-5. PubMed ID: 6265632
    [No Abstract] [Full Text] [Related]

  • 49. Intradermal treatment of cutaneous leishmaniasis with two antimonial drugs.
    Morsy TA, Essa MH, Aboul Anaan AM, Montasser MF.
    J Egypt Soc Parasitol; 1988 Jun 22; 18(1):341-4. PubMed ID: 2836525
    [No Abstract] [Full Text] [Related]

  • 50. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma.
    de Górgolas M, Castrillo JM, Fernández Guerrero ML.
    Clin Infect Dis; 1993 Jul 22; 17(1):56-58. PubMed ID: 8353246
    [Abstract] [Full Text] [Related]

  • 51. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
    Utili R, Rambaldi A, Tripodi MF, Andreana A.
    Infection; 1995 Jul 22; 23(3):182-3. PubMed ID: 7499009
    [Abstract] [Full Text] [Related]

  • 52. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
    Veiga JP, Rosa TT, Kimachi T, Wolff ER, Sampaio RN, Gagliardi AR, Junqueira Júnior LF, Costa JM, Marsden PD.
    Rev Inst Med Trop Sao Paulo; 1985 Jul 22; 27(6):298-302. PubMed ID: 3014634
    [No Abstract] [Full Text] [Related]

  • 53. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
    Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C.
    Am J Trop Med Hyg; 1997 Dec 22; 57(6):651-5. PubMed ID: 9430521
    [Abstract] [Full Text] [Related]

  • 54. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
    Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y.
    Arch Dermatol; 2006 Dec 22; 142(12):1575-9. PubMed ID: 17178983
    [Abstract] [Full Text] [Related]

  • 55. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.
    J Infect; 2006 Jul 22; 53(1):e25-7. PubMed ID: 16274744
    [Abstract] [Full Text] [Related]

  • 56. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy.
    Villanueva JL, Alarcón A, Bernabeu-Wittel M, Cordero E, Prados D, Regordán C, Alvar J.
    Eur J Clin Microbiol Infect Dis; 2000 Oct 22; 19(10):798-801. PubMed ID: 11117648
    [Abstract] [Full Text] [Related]

  • 57. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN.
    Trans R Soc Trop Med Hyg; 2001 Oct 22; 95(6):668-72. PubMed ID: 11816442
    [Abstract] [Full Text] [Related]

  • 58. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G.
    Clin Infect Dis; 2005 May 15; 40(10):1395-403. PubMed ID: 15844060
    [Abstract] [Full Text] [Related]

  • 59. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 60. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
    Trinchieri V, Ferone U, Monacelli M, Isceri L, Proietti F, Sorice F.
    Riv Eur Sci Med Farmacol; 1996 Aug 01; 18(2):49-51. PubMed ID: 9213843
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.